Results of a secondary analysis of two pivotal studies were presented today at the 71st Annual Meeting of the American College of Gastroenterology (ACG), and showed that 60 percent of patients treated ...

Bethesda, Md., and Deerfield, Ill., May 27, 2008 – Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA® (lubiprostone) 8 mcg ...

The Food and Drug Administration on Tuesday approved the first U.S. drug to treat irritable bowel syndrome with constipation in adult women, a medicine marketed by Takeda Pharmaceutical Co and its ...

Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...

First treatment approved for opioid-induced constipation The FDA has expanded the indication for oral lubiprostone (Amitiza) to include opioid-induced constipation in chronic pain patients. The FDA ...

, a global pharmaceutical company, today announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine ...